These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 20407632)
1. Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update. Destro M; Cagnoni F; D'Ospina A; Ricci AR; Demichele E; Peros E; Zaninelli A; Preti P Vasc Health Risk Manag; 2010 Apr; 6():253-60. PubMed ID: 20407632 [TBL] [Abstract][Full Text] [Related]
2. Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ. Duprez D; Ferdinand K; Purkayastha D; Samuel R; Wright R Vasc Health Risk Manag; 2011; 7():701-8. PubMed ID: 22174580 [TBL] [Abstract][Full Text] [Related]
3. Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients. Destro M; Crikelair N; Yen J; Glazer R Vasc Health Risk Manag; 2010 Sep; 6():821-7. PubMed ID: 20859551 [TBL] [Abstract][Full Text] [Related]
4. Randomized study to compare valsartan +/- HCTZ versus amlodipine +/- HCTZ strategies to maximize blood pressure control. Zappe D; Papst CC; Ferber P; Vasc Health Risk Manag; 2009; 5():883-92. PubMed ID: 19898644 [TBL] [Abstract][Full Text] [Related]
5. Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study. Wright RF; Duprez D; Purkayastha D; Samuel R; Ferdinand KC J Clin Hypertens (Greenwich); 2011 Aug; 13(8):588-97. PubMed ID: 21806769 [TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups. Assaad-Khalil SH; Najem R; Sison J; Kitchlew AR; Cho B; Ueng KC; DiTommaso S; Shete A Vasc Health Risk Manag; 2015; 11():71-8. PubMed ID: 25653536 [TBL] [Abstract][Full Text] [Related]
7. [Medication of the month. Exforge HCT: combination of amlodipine besylate, valsartan and hydrochlorothiazide in a single tablet]. Lancellotti P Rev Med Liege; 2010; 65(7-8):471-5. PubMed ID: 20857707 [TBL] [Abstract][Full Text] [Related]
9. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension. Frampton JE; Scott LJ Am J Cardiovasc Drugs; 2009; 9(5):309-30. PubMed ID: 19791840 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306 [TBL] [Abstract][Full Text] [Related]
11. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine. Ferri C; Croce G; Desideri G Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492 [TBL] [Abstract][Full Text] [Related]
12. Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension. Calhoun DA; Lacourcière Y; Crikelair N; Jia Y; Glazer RD Curr Med Res Opin; 2013 Aug; 29(8):901-10. PubMed ID: 23721363 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study. Lee IT; Hung YJ; Chen JF; Wang CY; Lee WJ; Sheu WH Clin Ther; 2012 Aug; 34(8):1735-50. PubMed ID: 22784975 [TBL] [Abstract][Full Text] [Related]
14. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Calhoun DA; Lacourcière Y; Chiang YT; Glazer RD Hypertension; 2009 Jul; 54(1):32-9. PubMed ID: 19470877 [TBL] [Abstract][Full Text] [Related]
15. MANAGEMENT OF RISKS OF ADVERSE DRUG REACTIONS ACCORDING TO ADR REPORT FORM DATA FROM LVIV REGION HEALTHCARE FACILITIES IN 2022. Stepaniuk N; Piniazhko O; Poshyvak O; Bessarab T; Hudz N; Gavriluk I Georgian Med News; 2023; (340-341):76-80. PubMed ID: 37805878 [TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Malacco E; Varì N; Capuano V; Spagnuolo V; Borgnino C; Palatini P; Clin Ther; 2003 Nov; 25(11):2765-80. PubMed ID: 14693303 [TBL] [Abstract][Full Text] [Related]
17. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. Deeks ED Am J Cardiovasc Drugs; 2009; 9(6):411-8. PubMed ID: 19929039 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan. da Silva PM Clin Drug Investig; 2010; 30(9):625-41. PubMed ID: 20626210 [TBL] [Abstract][Full Text] [Related]
20. Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine. Palatini P; Malacco E; Di SS; Carretta R; Dorigatti F; Bertocchi F; Mann J Eur J Clin Pharmacol; 2002 Jan; 57(11):765-70. PubMed ID: 11868797 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]